Saturday, April 20, 2024

A Groundbreaking 20-Year Rechargeable Sacral Neuromodulation System for Bladder and Bowel Management

Similar articles

Axonics has revealed that its latest innovation, the R20 rechargeable sacral neuromodulation (SNM) system, has obtained CE Mark approval, signifying its suitability for use in adults suffering from overactive bladder and/or fecal incontinence. This implant boasts remarkable longevity within the body, promising a lifespan of at least 20 years. Notably, the R20 system aims to alleviate the burden of frequent recharging, as it requires replenishment only once every six to 10 months, with each session lasting just one hour.

The sacral neuromodulation system, characterized by its compact 5cc form factor, maintains the same size as its predecessor, the R15 iteration, ensuring consistency and familiarity for both healthcare providers and patients. Despite its unassuming size, the R20 system incorporates cutting-edge features that enhance its functionality and usability.

One notable aspect of the sacral neuromodulation system is its tined lead, meticulously designed to prevent migration within the body. This feature is crucial for ensuring the long-term effectiveness of the implant and minimizing the need for repositioning or replacement procedures. Furthermore, the implant is equipped with visible and radiopaque markers, facilitating precise placement during surgical implantation procedures. This precision is essential for optimizing therapeutic outcomes and minimizing the risk of complications.

Complementing the implant’s sophisticated design is the patient remote control, a user-friendly device that enhances the overall treatment experience. Unlike traditional remote controls that require frequent recharging, the sacral neuromodulation system remote control operates without the need for external power sources. This eliminates the hassle of battery replacement and ensures uninterrupted access to therapy adjustments and monitoring functionalities.

R20 System Innovates Patient Care with Wireless Charging and Personalized Therapy Control

One of the key features of the remote control is its ability to alert users when recharging the implant is necessary. This proactive notification system helps patients stay informed and ensures timely maintenance of the device’s battery life. Additionally, the remote control enables remote monitoring, allowing healthcare providers to assess the device’s status and performance without the need for in-person appointments. This capability is particularly valuable for patients with busy schedules or limited mobility.

Moreover, the remote control facilitates the adjustment of therapy levels, catering to the individual needs of patients undergoing both trial and permanent treatments. This flexibility empowers patients to personalize their therapy settings according to their comfort and therapeutic requirements, enhancing treatment efficacy and overall satisfaction.

Charging the sacral neuromodulation system is a seamless process, thanks to its wireless charging technology. The implant can be charged through the skin using a stretchable belt worn around the waist, providing a convenient and discreet charging solution. This innovative charging method eliminates the need for cumbersome cables or external charging devices, simplifying the patient’s daily routine and enhancing the overall user experience.

Sacral Neuromodulation

Setting a New Global Standard in Sacral Neuromodulation for Bladder and Bowel Control

In summary, the sacral neuromodulation system represents a significant advancement in sacral neuromodulation technology, offering a blend of compact design, advanced features, and user-friendly functionalities. With its precise placement capabilities, long-lasting performance, and convenient remote control, the sacral neuromodulation system sets a new standard for the management of overactive bladder and fecal incontinence.

In comparison to its predecessor, the R20 system boasts enhanced programming capabilities and expanded MRI labeling, empowering physicians and patients alike with greater flexibility and confidence. Anticipated to hit the European market by mid-April, the R20 system had previously obtained approval from Health Canada in December 2022, followed by FDA approval in January 2023.

Raymond W. Cohen, the CEO of Axonics, emphasized the company’s unwavering commitment to improving patient experiences through innovation in SNM technology. Cohen highlighted the paramount importance of efficacy and durability in addressing the chronic conditions of patients with overactive bladder. He hailed the R20 system as a significant advancement in rechargeable neuromodulation devices, signaling Axonics’ dedication to continuous improvement. Cohen expressed confidence in the potential of Axonics’ innovative solutions to drive significant growth in both the U.S. and international markets in the years ahead.

 

Resource: Mddi Online, March 14, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article